Ascendis Pharma A/S filed a Form 6-K on October 26, 2026, reporting pooled kidney function data from its Phase 2 PaTH Forward and Phase 3 PaTHway trials of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism, presented at Kidney Week 2026.

Key Highlights

  • eGFR improvement at Week 52: Mean improvement in estimated glomerular filtration rate (eGFR) from baseline to Week 52 was 9.6 mL/min/1.73 m2, with statistically significant increases from Week 26 onward (p<0.0001).
  • Sustained kidney gains over 5 years: From Week 52 to Week 266, the mean eGFR slope was 0.28 mL/min/1.73 m2/year, according to the filing.
  • 68.9% reached clinically meaningful eGFR gain: By Week 52, 68.9% of patients had an eGFR increase of at least 5 mL/min/1.73 m2, and 49.6% achieved an increase greater than 10 mL/min/1.73 m2.
  • Urine calcium normalized: Mean 24-hour urine calcium excretion fell from 396 mg/day at baseline to 206 mg/day at Week 26 and further to 170 mg/day at Week 52.
  • High independence from conventional therapy: 98% of patients achieved independence from active vitamin D and 95% achieved independence from therapeutic doses of calcium at the final trial visit.
  • Pooled population: The analysis covered 139 patients who received at least one dose of TransCon PTH across both trials, of whom 129 completed the final trial visit.
  • Safety profile: According to the filing, TransCon PTH "was generally well tolerated, with no new safety signals identified," and most treatment-emergent adverse events were Grade 1 or 2.

Pooled Kidney Data from PaTH Forward and PaTHway Trials Presented at ASN Kidney Week 2026

Ascendis Pharma A/S (NASDAQ:ASND) disclosed the results of a pooled, post-hoc analysis of kidney function data from its Phase 2 PaTH Forward and Phase 3 PaTHway trials in a poster presented by nephrologist Elvira Gosmanova, M.D., Professor of Medicine at Albany Medical College, at the American Society of Nephrology's annual meeting on October 26, 2026. The combined trials enrolled 141 adults with hypoparathyroidism, with the pooled kidney analysis covering the 139 patients who received at least one dose of TransCon PTH (palopegteriparatide).

According to the filing, mean improvement in eGFR from baseline to Week 26 was 7.2 mL/min/1.73 m2 and reached 9.6 mL/min/1.73 m2 by Week 52. Increases from baseline were statistically significant from Week 26 through trial completion (p<0.0001). The filing further reports that patients with a baseline eGFR below 60 mL/min/1.73 m2 had a numerically greater increase in mean eGFR than those with a baseline eGFR at or above 60 mL/min/1.73 m2. Mean baseline eGFR for the pooled analysis was 69 (17) mL/min/1.73 m2, and a minimum eGFR of 30 mL/min/1.73 m2 was required for trial eligibility.

The filing notes that 24-hour urinary calcium excretion normalized progressively, from a mean of 396 mg/day at baseline to 170 mg/day at Week 52, with improvements sustained through the end of the trials. Mean serum calcium increased within the normal range to 8.9 mg/dL, and 88% of patients had normal albumin-adjusted serum calcium levels at the final trial visit. The filing contains forward-looking statements, which Ascendis cautions are subject to substantial risks and uncertainties as described in its Annual Report on Form 20-F filed February 11, 2026.

What Was Disclosed

Ascendis Pharma filed a Form 6-K reporting pooled kidney function results from two hypoparathyroidism trials of TransCon PTH, covering 139 patients over up to 5 years, with data on eGFR, urinary calcium, serum calcium, and independence from conventional therapy.